Compass Therapeutics (CMPX) Operating Leases (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Operating Leases for 3 consecutive years, with $8.8 million as the latest value for Q4 2025.
- Quarterly Operating Leases rose 40.23% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, up 40.23% year-over-year, with the annual reading at $8.8 million for FY2025, 40.23% up from the prior year.
- Operating Leases hit $8.8 million in Q4 2025 for Compass Therapeutics, roughly flat from $8.8 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $9.6 million in Q2 2025 to a low of $536000.0 in Q4 2023.
- Historically, Operating Leases has averaged $5.1 million across 3 years, with a median of $6.3 million in 2024.
- Biggest YoY gain for Operating Leases was 1074.63% in 2024; the steepest drop was 46.52% in 2024.
- Year by year, Operating Leases stood at $536000.0 in 2023, then soared by 1074.63% to $6.3 million in 2024, then skyrocketed by 40.23% to $8.8 million in 2025.
- Business Quant data shows Operating Leases for CMPX at $8.8 million in Q4 2025, $8.8 million in Q3 2025, and $9.6 million in Q2 2025.